Qiagen received CE IVD marking for its NeuMoDx Flu A-B/RSV/SARS-CoV-2 Vantage Test and for a saliva collection kit for its single-plex NeuMoDx SARS-CoV-2 assay.
The company recently received FDA Emergency Use Authorization for its SARS-CoV-2 PCR test while its data-driven COVID-19 research initiative is moving along.
The company said its clinical lab revenues rose nearly 5 percent, but revenues from its life sciences business fell 26 percent because of the COVID-19 pandemic.
BioFire's test is designed to detect and differentiate between SARS-CoV-2 and other respiratory pathogens, while UMass Medical's test is only for SARS-CoV-2.